Feb 11 (Reuters) - Gilead Sciences (GILD.O), opens new tab posted fourth-quarter results that exceeded Wall Street expectations and forecast 2025 earnings above analyst estimates on Tuesday ...

An atmospheric river is expected to arrive Wednesday night, bringing "heavy and impactful" rainfall to central and Southern California through Thursday night. A forecast map from the NWS indicated ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415 million. The agreement includes an upfront ...

Gilead Sciences' TROP2-directed drug Trodelvy has missed the target in another clinical trial, this time in urothelial carcinoma, the most common form of bladder cancer. The results of the TROPiCS ...

Gilead Sciences, a leader in HIV drugs, faces revenue growth challenges as its blockbuster drugs lose exclusivity by 2033, making diversification crucial. The current stock price at $95+ implies 5 ...

(UBER), Comcast Corp. (CMCSA) and Gilead Sciences, Inc. (GILD), as well as a micro-cap stock Onfolio Holdings, Inc. (ONFO). The Zacks microcap research is unique as our research content on these ...

Note: Map contains unchecked data from automatic equipment. Please remember to refresh page so the data is up to date. Move mouse over station for more data.